AU4205597A - Methods for prevention of cellular proliferation and restenosis - Google Patents

Methods for prevention of cellular proliferation and restenosis

Info

Publication number
AU4205597A
AU4205597A AU42055/97A AU4205597A AU4205597A AU 4205597 A AU4205597 A AU 4205597A AU 42055/97 A AU42055/97 A AU 42055/97A AU 4205597 A AU4205597 A AU 4205597A AU 4205597 A AU4205597 A AU 4205597A
Authority
AU
Australia
Prior art keywords
restenosis
prevention
methods
cellular proliferation
proliferation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU42055/97A
Inventor
Margaret Forney Prescott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG, Novartis AG filed Critical Ciba Geigy AG
Publication of AU4205597A publication Critical patent/AU4205597A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11013—Protein kinase C (2.7.11.13)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU42055/97A 1996-08-20 1997-08-18 Methods for prevention of cellular proliferation and restenosis Abandoned AU4205597A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2421996P 1996-08-20 1996-08-20
US60024219 1996-08-20
US2507296P 1996-08-30 1996-08-30
US60025072 1996-08-30
PCT/EP1997/004503 WO1998007415A2 (en) 1996-08-20 1997-08-18 Methods for prevention of cellular proliferation and restenosis

Publications (1)

Publication Number Publication Date
AU4205597A true AU4205597A (en) 1998-03-06

Family

ID=26698189

Family Applications (1)

Application Number Title Priority Date Filing Date
AU42055/97A Abandoned AU4205597A (en) 1996-08-20 1997-08-18 Methods for prevention of cellular proliferation and restenosis

Country Status (3)

Country Link
AU (1) AU4205597A (en)
ID (1) ID18301A (en)
WO (1) WO1998007415A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6190869B1 (en) 1999-10-26 2001-02-20 Isis Pharmaceuticals, Inc. Antisense inhibition of protein kinase C-theta expression
US6641611B2 (en) 2001-11-26 2003-11-04 Swaminathan Jayaraman Therapeutic coating for an intravascular implant
IL161156A0 (en) 2001-10-30 2004-08-31 Novartis Ag Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
DE102004019413A1 (en) * 2004-04-19 2005-11-24 Phenos Gmbh Use of substances (e.g. nucleic acids, proteins and peptides), which restrain/reduce the expression and/or activity of protein kinase C-epsilon for the treatment/prevention of e.g. circulatory and vascular diseases
US8088789B2 (en) 2006-09-13 2012-01-03 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
CN101557814B (en) 2006-09-13 2015-05-20 万能医药公司 Macrocyclic lactone compounds and methods for their use
US10695327B2 (en) 2006-09-13 2020-06-30 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
DE3937015A1 (en) * 1988-11-10 1990-05-17 Hoechst Ag USE OF ETHYLENE DIAMETRA ACID ACID AS AN INHIBITOR OF THE CALCIUM / CALMODULIN DEPENDENT PROTEIN KINASE II OR THE PROTEIN KINASE C
US5242397A (en) * 1989-06-20 1993-09-07 Cedars-Sinai Medical Center Catheter device and method of use for intramural delivery of protein kinase C and tyrosine protein kinase inhibitors to prevent restenosis after balloon angioplasty
EP0541486A1 (en) * 1991-11-07 1993-05-12 Ciba-Geigy Ag Polycyclic conjugates
WO1993019203A1 (en) * 1992-03-16 1993-09-30 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of protein kinase c
US5516775A (en) * 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives

Also Published As

Publication number Publication date
WO1998007415A2 (en) 1998-02-26
ID18301A (en) 1998-02-26
WO1998007415A3 (en) 1998-05-07

Similar Documents

Publication Publication Date Title
EP0971723A4 (en) Compositions and methods for inhibiting cellular proliferation
AUPN855496A0 (en) Prevention of proliferation of vascular cells
AU6893698A (en) Device and method for preventing restenosis
GB9711823D0 (en) Radio reciever and method of operation
IL139599A0 (en) Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
GB2303998B (en) Radio telephones and methods of operation
AU5797099A (en) Concealed colostomy apparatus and method
AU2553597A (en) Wideband digitization systems and methods for cellular radiotelephones
PL336582A1 (en) Leptin as an inhibitor of neoplastic cell proliferation
AU9016898A (en) Methods and compositions for treatment of restenosis
AU4639596A (en) Inhibition of glial cell proliferation
GB2309857B (en) Radio telephones and method of operation
AU5997398A (en) Radio telephone systems and methods of operation
AU2277597A (en) New inhibitors of sh2-mediated processes
AU4815397A (en) Method of disrupting cellular adhesion
AU4205597A (en) Methods for prevention of cellular proliferation and restenosis
AU3118297A (en) Sok-1 and methods of use
GB2303999B (en) Radio telephones and methods of operation
AU3389197A (en) $(d)-erythroid kruppel-like factors and methods of use
AU3410497A (en) Methods for the isolation and proliferation of insulin-secreting cells
PL328081A1 (en) Peptidic inhibitors of haematoblast proliferation
AU3459497A (en) Cancer cell proliferation inhibitors
ZA977433B (en) Methods for prevention of cellular proliferation and restenosis.
AU5778698A (en) Reduction of restenosis
AU3735900A (en) Methods of treatment and prevention of restenosis